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Institut Hiscia, Verein fu ¨r Krebsforschung, Arlesheim, Switzerland
In Europe many cancer patients use complementary therapies, particularly mistletoe. Only a
few controlled clinical trials have been performed with the mistletoe preparation Iscador as a
complementary treatment for cancer, many of them with medium to low quality due to
methodological shortcomings. Reasons for some quality concerns, particularly discontinuation
of treatment and/or participation and premature termination are analyzed. Analysis is based on
controlled clinical trials dealing with Iscador. Data stem from the archive of published and
ongoing research of the «Verein fu ¨ r Krebsforschung» (Society for Cancer Research) in
Arlesheim, Switzerland. Controlled clinical studies with cancer patients that were started after
01.01.1990 or were not completed by then have been evaluated. Fifty-six controlled studies are
documented, 24 of them randomized and 32 non-randomized. Nine of the randomized studies
were done by matched-pair design, the others by conventional parallel group design; six of the
last were terminated prematurely primarily for slow recruitment due to patient preferences and
compliance of physicians. Patient and physician preference seem to be important factors
limiting recruitment for randomized trials and hence implementation. This adds to the overall
unwillingness of participation by patients with serious diseases. A well-balanced mix of designs
using different research methods and outcomes is suggested combined with analyses, in
countries where mistletoe therapy in general or Iscador in particular is unknown or not
available.
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Background
In Europe, a substantial portion of patients suffering
from cancer use complementary therapies. However,
evidence of these treatments regarding efficacy on disease
progression and survival is discussed controversially (1).
Amongst complementary therapies against cancer,
aqueous extracts of European mistletoe (Viscum
album L.), developed on the basis of anthroposophical
medicine, are the most frequently used medications,
particularly in German speaking countries (2,3).
In recent systematic reviews (4–6) the authors concluded
that in spite of the longstanding and widespread use of
mistletoe preparations, only few controlled clinical trials
have been performed; the quality of many older studies
is generally medium to low due to methodological
shortcomings, the more recent ones tend to be better.
Objective
Reasons for some specific quality issues, particularly
discontinuation of treatment and/or participation and
premature termination of recent controlled clinical
studies with cancer patients using the mistletoe prepara-
tion Iscador as a complementary treatment are analyzed.
Consequences for future research are suggested.
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Unfulfilled quality criteria in published research reveal
some of the difficulties that mistletoe might encounter
but are in some cases not specific for mistletoe. However,
looking for concerns intrinsic to research with the
mistletoe preparation Iscador, additional information
can be gained from difficulties with ongoing research
and from reasons for discontinuation. The following
analysis is based on controlled clinical studies dealing
with the mistletoe preparation Iscador (see subsequently).
All data stem from the archive of published and ongoing
research of the «Verein fu ¨ r Krebsforschung» (Society for
Cancer Research) in Arlesheim, Switzerland. In order to
concentrate the analysis on newer research, only con-
trolled clinical studies with cancer patients that were
started after 01.01.1990 or were not completed by then
have been evaluated, including non-finished and non-
published ones (7,8). The control group always received
conventional cancer therapy (adjuvant or palliative) and
the treatment group additionally Iscador. Within this
time frame, 56 controlled studies are documented, 24 of
them randomized and 32 non-randomized (Figure 1).
Subgroups of these will be discussed separately.
For the discussion of research with other mistletoe
products than Iscador and concerning other quality
issues, see e.g. (3,4,6,9). References also give a detailed
quality assessment of controlled clinical studies with
mistletoe preparations (4,6,9).
Mistletoe Characteristics
Mistletoe extracts for cancer therapy were first used in
1918 by Ita Wegman on the basis of anthroposophy (10).
Pharmacological and toxicological properties of mistletoe
extracts are documented by various publications on
immunological and anti-cancer effects in vitro and
in vivo [overviews in (3,11–14)]. Iscador is a fermented
aqueous extract of European mistletoe (Viscum album L.)
that is treated by a special mechanical process of
anthroposophical pharmaceutics to increase efficacy
(15). There are different doses and sorts of Iscador
depending on the host tree, and various
application schemes (12,16). Iscador is generally adminis-
tered subcutaneously two to three times a week. For
information concerning the specific therapy regimes, one
has to consult the original studies.
Systemic adverse reactions are very rare (3,17–20) and
mild to moderate in almost all cases (i.e. CTC/WHO
grade 1–2) with spontaneous recovery within one week
(21,22). No irreversible events or deaths were reported.
This means that there exists no real risk in using
mistletoe, which is an important condition for planning
and implementing mistletoe studies even if the clinical
effects are still discussed controversially (1). However,
local reactions at the injection site are frequent with
spontaneous recovery after some hours or days. These
effects are expected and typical for mistletoe prepara-
tions, especially Iscador: in consequence, the dose is
adjusted according to the size of the local reaction. This
makes it difficult to design a pharmacologically and
medically inert placebo showing similar reactions (23).
Given this situation, blinding of patients and physicians
is nearly impossible. In case a placebo with a similar set
of reactions is used, the placebo might not be a true
placebo (showing no specific effects) any more and thus
results of the treatment comparison might be at least
questionable.
Randomized Iscador Studies with Parallel-
group Design
From 15 randomized Iscador studies with parallel-group
design (Table 1) six had to be terminated prematurely
(No. 3, 4, 6–9). In five cases (No. 3, 6–9) the most
important reason was slow recruitment, due to
Randomized studies with
parallel-group design
n = 15
Randomized studies with
matched-pairs design
n = 9
Randomized studies
n = 24
Prospective controlled
non-randomized studies
with parallel-goup design
n = 9
Prospective controlled
non-randomized studies
with matched-pairs design
n = 16
Prospective controlled
non-randomized studies
n = 25
Retrospective forward
longitudinal (retrolective)
cohort studies
n = 4
Retrospective controlled
studies
n = 3
Retrospective controlled
studies
n = 7
Non-randomized controlled studies
n = 32
Controlled Iscador studies
with cancer patients started after or
not finished by 01.01.1990
n = 56
Figure 1. Controlled clinical studies for cancer patients with the mistletoe preparation Iscador; started after or not finished by 01.01.1990.
20 Controlled studies with mistletoe preparation IscadorTable 1. Randomized mistletoe studies with Iscador in parallel-group design
Study
No.
Indication Outcome parameter Patients
(planned)
Status Reasons for termination
1 Non-small-cell
lung cancer
Overall survival 86 Iscador/97 control Start 1981, published
1991 (34)
–
2 Melanoma Disease-free-interval,
overall survival
2102 Start 1988, published
2004 (35)
–
3 Advanced cancer QoL (QLQ-C30, SELT, HADS) (340) Start 1995, terminated 1998 Slow recruitment (patient preferences,
language barriers, logistical problems,
refusal of participation in trial),
drop-outs because of death (36)
4 Colon cancer, stage III Disease-free survival,
global QoL
(3150) Start 1996, terminated 1996 After study start: negative expert opinion
from DKG (Deutsche Krebsgesellschaft)
concerning insufficient data for mistletoe
which lead to termination
5 Breast cancer QoL (Spitzer) 20 Iscador/10 control Start 1997, published
1999 (37)
–
6 Throat, nose and
ear cancer
Side effects of radiation
therapy (immune
system, DNA, infections)
(220) Start 1997, terminated 1999 Slow recruitment (suboptimal motivation
and compliance of physicians,
compliance of patients)
7 Breast cancer Immunological side
effects of radiation
therapy after operation, QoL
(260) Start 1997, terminated 2005 Slow recruitment (patient preferences,
refusal), many drop-outs (compliance/motivation
of physicians), shut down of radiation department
8 Bladder cancer Safety of pre-operative
Iscador instillation,
anti-tumor effects, QoL
(213) Start 1999, terminated 2003 Slow recruitment (patient preferences, refusal),
suboptimal motivation and compliance
of physicians
9 Small-cell lung cancer QoL (QLQ-C30),
disease-free interval,
overall survival
(247) Start 2000, terminated 2001 very slow recruitment
10 Colorectal cancer Natural killer cell activity during
peri-operative Iscador infusion
221 Recruitment 2002–2004,
published 2007 (38)
–
11 Non-small-cell
lung cancer
Overall survival,
progression-free interval,
QoL (QLQ-C30), immunological
parameters, safety
(225) Recruitment 2004–2007 –
12 Breast cancer QoL, cortisol level, immunological
parameters
224 Recruitment 2005–2006,
published 2004/5 (39,40)
–
13 Breast cancer QoL (QLQ-C30), fatigue, neutropenia,
immunological parameters
(330) Recruitment 2005–2006 –
14 Colon cancer with
metastases
QoL (QLQ-C30), ECOG, tolerability,
overall survival
(225) Start 2005 –
15 Spindle-cell
bone-sarcoma
Post-relapse disease-free
survival, QoL (QLQ-C30)
(218) Start 2007 –
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1insufficient compliance on the physicians’ side (preference
for other ongoing studies: i.e. recruitment for trials with
conventional drugs if available; no equipoise in view of
mistletoe treatment with Iscador; lack of methodological
education for performing clinical trials) and on the
patients’ side [refusal of participation in trial, therapy
preferences, in favor of Iscador; see also (23)]. However,
trial participation generally has many hurdles and is
particularly bad with patients having therapy preferences
(24–29). The situation concerning recruitment and
compliance in randomized studies is even more compli-
cated in the context of complementary oncology com-
pared to conventional oncology (3,30–33).
Obviously, these difficulties were also encountered in
completed studies. For instance, in a large trial in
Germany during the eighties, the investigators had to
revise the power calculation twice to reduce sample size,
but still needed more than 9 years for patient recruitment
(41). Another study needed considerably more time for
completion than anticipated (35,42). In addition, for both
cases showing no significant effect of Iscador on tumor
progression or survival, one can argue that they suffered
from a false-negative bias (3,4,6). Given these experi-
ences, an empirical study was conducted to evaluate the
willingness of patients to participate in a randomized
clinical mistletoe trial (39). The results are shown in
Table 2 and present a whole bundle of reasons why
particular patients were not able to enter the trial.
Among these, preference of mistletoe is the only
mistletoe-specific reason for not participating. The refusal
of trials in general as well as the wish to determine the
therapy itself is prominent as well.
Randomized Matched-pair Studies
with Iscador
The concept of randomized matched-pair studies is
rather unusual in cancer research. The recruitment and
randomization of patients for this kind of trial is
executed pair-wise: From a successively filled pool of
cancer patients not treated by any kind of mistletoe or
therapy stimulating the immune system, pairs according
to pre-specified prognostic factors are built and then
randomized separately. Details of the randomization
process (43) were executed according to pre-specified
rules, in accordance with the suggestions of the
CONSORT statement (44,45).
Randomization and Concealed Allocation
Two slips of paper with names of the two matched
partners were put into a hat by the primary investigator,
and a masked assistant drew one of the slips. It was
determined that the patient selected first was asked if he
or she would be willing to ask the attending doctor for a
complementary therapy using Iscador. Thus, intervention
did not consist of giving a therapy with Iscador, but of
making a suggestion for an Iscador therapy.
Implementation
The patient recruitment happened strictly according to
the matching rules without interference from investiga-
tors. The random allocation result was implemented by
the primary investigator non-involved in the random
selection process.
Consent
The acceptance of participation in this kind of study is
one-sided, i.e. only the patient being suggested a therapy
with Iscador was informed about this process. The other
patient as well as the respective attending physician
was left uninformed. Thus, this is a special case of
the single randomized consent design of Zelen (46–48).
That research was planned and started in the early 70s,
where ethical committees did not yet exist; or there was
Table 2. Example: recruitment and randomization in mistletoe studies (39)
N Characteristics Exclusion Reasons for exclusion
1922 Breast operation from May 1999 to August 2001
in Heidelberg university hospital
518 Only biopsy, benign tumor
1404 Diagnosis breast cancer 883 Inclusion criteria not fulfilled or exclusion criteria fulfilled:
no primary breast cancer (316), other stage (105), pre-operative
chemotherapy (72), age (63), other missing inclusion criteria (73),
other exclusion criteria (254)
521 Post-operative check of inclusion and exclusion
criteria with clinical registry
367 Refusal of trial in general (184), logistics (74), mistletoe preferred (51),
no histology (42), participation in other study (13), refusal
of chemotherapy (3)
154 Patient interview: all inclusion and
exclusion criteria OK
80 No chemotherapy (55) or other chemotherapy (inclusion criteria) (19),
other reasons (6)
74 Study group 45 Prefers to determine the therapy (22), prefers mistletoe (14), prefers no
injections (4), other (5)
29 Willing to be randomized
22 Controlled studies with mistletoe preparation Iscadorat least no mandatory requirement to have a study
approved by them; however, one does not know their
reaction on such a study proposal.
Exclusion of Pairs
If for any reason, a single patient had to be excluded,
the whole matched-pair including this patient was
excluded. The following criteria were applied to exclude
patient pairs: (i) if the allocated suggestion for Iscador
therapy has not been taken up either by the patient or
the attending physician; (ii) if the control partner decided
to start Iscador therapy or any other treatment modulat-
ing the immune system; (iii) if for one of the partners a
certified non-tumor-related accident or suicide occurred;
(iv) if after the matching process any patient refused
to participate further for any reason, or if any partner
dropped out for any other reason than death or if a
patient could not be found any more in the follow-up
process.
The statistical analysis of randomized clinical trials
according to the principle of intention-to-treat (53,54) has
two aspects which need to be differentiated: first to
preserve the statistical balance of the baseline factors in
the two therapy groups and second to present an
adequate picture of the real life situation, where non-
compliance and drop-out occur and might be associated
with the therapy and the outcome. However, a suffi-
ciently complete picture of the whole situation is only
given if the intention-to-treat analysis estimating the
effect of assignment to therapy (use-effectiveness) is
complemented with an estimated effect of actually
administered therapy (method-effectiveness—not to be
confused with a simple per-protocol—or as-treated
analysis) (55,56).
With respect to randomized matched-pair studies,
the procedure of exclusion of pairs guarantees that
randomization is not undermined by excluding patients.
In other words, internal validity is not at issue since
the structural comparability is preserved by pair-wise
selection and exclusion. This covers the first aspect of an
intention-to-treat analysis. However, by this exclusion
process, not all randomized pairs are included in the
analysis and hence there exists a kind of underreporting
bias which does not interfere with the randomization
but with the completeness of the analyzed data sets.
A masking process was not applicable to the intervention
of the randomized matched-pair studies, since it consisted
not of a therapy as such but of a suggestion to perform a
therapy with Iscador towards the randomly selected
patient. In addition, neither the outcome assessors were
masked nor the statisticians.
Nine studies of this kind have been executed (Table 3),
four of which have been published (49,50,52,57–59) and
the rest await final analysis and publication. Most of
these took a very long time to execute (more than 10
years) and there have been some patients who declined
participation or did not receive Iscador therapy (Table 3).
Concerns with Randomized Clinical Trials using Iscador
According to the aforementioned results reported,
recruitment for a conventional randomized controlled
clinical trial (RCT) is difficult for several reasons:
physician or patient preferences either in favor of or
against mistletoe therapies, preferred co-interventions,
patient and physician compliance and drop-outs. The
long tradition of using mistletoe preparations in German
speaking countries has the consequence that mistletoe
in general and Iscador in particular is well known among
Table 3. Randomized mistletoe studies with Iscador in matched-pair design; outcome is in all cases overall survival and psychosomatic self-regulation
Study centers Indication Pairs of Patients Status
Recruited Therapy declined
or not received
Drop-out
or lost
Final
Fifteen in Germany Breast cancer without
recurrences or metastases
59 19 2 38 Published 2006 (49)
Fifteen in Germany Breast cancer with
lymphatic metastases
17 0 0 17 Published 2001 (50,51)
Eight in Germany Cancer of the cervix
with metastases
19 0 0 19 Published 2007 (52)
Eight in Germany Cancer of the uterus
body without metastases
38 7 1 30 Publication in preparation
Eight in Germany Cancer of the uterus
body with metastases
26 0 0 26 Publication in preparation
Eight in Germany Cancer of the ovaries
without metastases
25 4 0 21 Publication in preparation
Eight in Germany Cancer of the ovaries
with metastases
24 4 0 20 Publication in preparation
Fifteen in Germany Several solid cancers 49 9 1 39 Published 2001 (50)
Eight in Germany Melanoma 22 0 0 22 Publication in preparation
eCAM 2009;6(1) 23cancer patients searching for complementary treatments.
Thus, many informed patients explicitly want to use
mistletoe extracts and therefore cannot be randomized.
Apart from this situation there are major general
concerns using randomization and blinding in trials
within complementary medicine (33). With respect to
quality, blinding is nearly impossible in mistletoe studies:
it was shown that at least in the long run most physicians
and patients loose their blindness (23,60). However,
also in chemotherapy trials, blinding is rare (61).
In addition, any kind of standardized therapy as used
in conventional randomized clinical trials is not repre-
sentative of a population using the mistletoe preparation
Iscador as a cancer treatment.
Randomized matched-pair studies have the drawback
of not being well accepted by conventional trial experts
and methodologists because of the unusual design. And,
they share some of the limitations of RCTs in general
which make recruitment and implementation difficult:
physician or patient preferences in favor of or against
complementary treatments, patient preferences, refusal to
trial in general, compliance, drop-outs, rigid inclusion
and exclusion criteria. Furthermore, a fairly big pool of
cancer patients is required to recruit enough matching
pairs. Not all quality issues concerning randomized
mistletoe research can be mentioned here. Some authors
(3,4,6) discuss other limits, particularly false-negative bias
stemming from other kinds of biases.
Prospective Non-randomized Controlled
Iscador Studies
Prospective non-randomized controlled studies are
advantageous for including representative samples of
patients and doing research on those receiving actual
Iscador treatments, i.e. performing prospective data
measurement. However, since they should consider all
known possible prognostic factors and confounders,
they tend to be expensive and, if the effect is not
strong, unreliable due to selection bias (62,63). Table 4
shows the nine controlled prospective non-randomized
studies in parallel-group design with Iscador that were
recently finished or are still ongoing. According to the
quality assessments of some of these in (4,6), they vary in
quality. Compared to other types of cohort research
(21,22) few patients are included, but compared to the
randomized trials, the situation is acceptable. Note that
none of them was discontinued.
The main work in realizing cohort studies should
focus on the design and implementation phase. That is
the place where random as well as systematic errors (bias)
can be minimized, particularly by specifying adequate
inclusion and exclusion criteria, and where adequate
measures against selection bias (the biggest challenge for
non-randomized designs), performance bias, detection
bias and attrition bias (80,81) can be provided. In a
systematic way, this has only been regarded in the four
parallel-group studies: No. II, V, VI, VII and, to some
extent, in study VIII with matched-pairs. The report on
random and systematic error prevention is insufficient
within the others (82), as is the statistical analysis.
Prospective Non-randomized Matched-pair
Studies with Iscador
There are 16 prospective non-randomized matched-pairs
studies with Iscador for different solid cancers, eleven
published (50,52,57–59); the remaining still await analysis
and publication.
Pair-wise matching is one of the strongest measures
against selection bias in non-randomized cohort research.
Within these, not only tumor-specific prognostic factors
are considered, but also the year of diagnosis: for
matching pairs, difference between the years of initial
diagnosis is at most 3 years. This allows patient
recruitment in pairs over a long period of time (and
hence long periods of follow-up) without risking the
danger of significantly different prognostic or therapeutic
procedures due to medical progress. In other words: there
is no danger of stage migration (83).
If for any reason a single patient was excluded, in any
case the whole matched-pair including this patient was
excluded. These pairs have neither been followed up nor
used for other purposes in any other Iscador research.
This process does not explicitly favor one of the two
therapy groups. In most cases, the excluded patient
pairs did not exceed 10% of those recruited. No study
was prematurely terminated due to lack of patients.
However, the recruitment period in most cases exceeded
10 years.
Controlled Forward Longitudinal
(«retrolective») Cohorts using Iscador
Controlled retrospective forward longitudinal
(«retrolective») cohort analyses (84) include systematic
searches of patient archival data in clinical registries
according to specific criteria of inclusion and exclusion,
guided by a protocol that adheres to the principles of
good epidemiological practice (85,86). These are advan-
tageous for being easy to implement for a long treatment
period in a comparatively short data gathering period for
a large sample. As such they give a picture of the real
world effectiveness, since they do not require any
additional selection process. The randomized selection
of study centers from an available pool guarantees
external validity. Their main disadvantage regards
reliance on complete archival data, that is on a retro-
spective data collection (i.e. measurements and recordings
of observations happened before study onset and for
24 Controlled studies with mistletoe preparation IscadorTable 4. Prospective controlled non-randomized mistletoe studies with Iscador in parallel-group design
Study No. Indication Outcome parameter Patients
Iscador/Control
Status Comments
I Cancer, different locations IL-6 in blood serum 99/28 Published 2000–04 (64–67) Evaluation of different patient
groups to measure the variations
of the IL-6 level in blood serum under
Iscador treatment compared to healthy controls
II Advanced cancer of
different locations
Socio-demographic and
medical characteristics
221/280 Published 2002 (68) Register study to evaluate patient characteristics
III Several gynecological cancers QoL 64/64 Published 2005 (69)
IV Several gynecological cancers Side effects of chemotherapy, QoL 43/41 Published 2005 (70)
V Primary breast cancer
without metastases
Immunological parameters,
QoL, safety
33/33 Published 2005 (40) Feasibility study to prepare a randomized
mistletoe trial
VI Breast cancer Granulocyte function, QoL 53/52 Published 2004/05 (71–73) Modulation of immune suppression due to
operation with peri-operative i.v. infusion of
Iscador, GCP quality standards
VII Breast cancer Immunological parameters, QoL,
tolerability of chemotherapy, safety
(50/50) Start of recruitment 2004,
preliminary publication (74)
Modulation of immune suppression due to
chemotherapy with i.v. infusion of Iscador
before and after chemotherapy; slow recruitment;
GCP quality standards
VIII Breast cancer Coping, QoL 60/60 Published 2001–06 (75–78) Coping was measured using the Mental Adjustment
to Cancer Scale (MAC), Iscador and control
patients were matched
IX Ear, nose and throat Microcirculation, immunological
parameters
10/10 Published 2005 (79) Small study to evaluate systemic and local
reactions at the injection site of Iscador treatment
(QoL, quality of life; GCP, good clinical practice)
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5different reasons). Therefore they are subject to selection
bias: measurements and recordings of all known prog-
nostic factors, possible confounders, and all wanted and
unwanted events cannot be assured. Four relevant studies
are available, two of which are finished and published
(21,22) and the remaining two are still being analyzed
and prepared for publication.
Retrospective Controlled Cohort Studies
with Iscador
Three classical retrospective cohort studies have been
performed since 1990 (87–89). They are easy to do and
complement the overall picture concerning characteristics
of the Iscador population.
Reflections and Consequences
Quality
There are avoidable problems of quality, such as
transparency and completeness of reporting data. Other
problems are more difficult to overcome; however, they
are not specific to mistletoe and induce different kinds of
biases (3,4,6): systematic differences in care provided
apart from the mistletoe treatment (performance bias),
dropouts, withdrawals and protocol deviations (attrition
bias). If the outcome is survival or tumor progression,
detection bias is not problematic. The situation for
quality of life is more complicated necessitating the use
of validated questionnaires.
Duration of clinical phase
Many mistletoe studies have a clinical phase of less than
12 months; one might argue, that this is insufficient to
bring into action long-term effects of mistletoe therapy
(81,84,90). More research on long-term applications
of Iscador is needed to evaluate effectiveness as well
as safety.
Designs
If one wants to compare parallel groups, continue to
randomize even if difficult. However, as shown earlier,
recruitment may be the utmost problem for randomized
trials with the mistletoe preparation Iscador. Before
rejecting randomization, one should search for alternative
designs for randomized trials [i.e. comprehensive cohort
design (91–93), and (94–96)]. Thus randomized matched-
pair studies might take a long time, depending on
availability of patients, but they seem to be an alternative
that requires evaluation. A survey within an academic
center in the USA showed that for conventional
physicians working in such an institution the attitude
towards using complementary therapy methods may be
strongly linked to the existence of randomized trials in
favor of such a treatment (97). However, randomization
does not solve all problems. If the number of recruited
patients is small, they might not be representative.
In addition, the use of randomization might severely
undermine the representativeness (or the generalizability)
of results, since patients who agree to randomization
might be different from those who do not, especially in
the context of complementary and alternative medicine,
where strong preferences are more common (36,68,98).
One of the most important points in this respect is to
use different designs that complement each other
(99,100). This was the underlying reason for implement-
ing randomized matched-pair studies together with
non-randomized ones (50). Thus, well-designed non-
randomized research is not just an excuse for not being
able to do randomized trials, but an important contribu-
tion to the overall clinical picture of Iscador therapy.
If randomization is not possible or can only be done in
small groups, one can use in addition prospective
controlled non-randomized studies (101,102) and adhere
to high quality standards (63,80,82). Under some
circumstances, results of prospective controlled non-
randomized studies might be comparable to randomized
for the same outcome and similar population character-
istics (103–106). However, care is required to prevent
overestimation (62,63,82). If resources and time frames
are limited, they can be complemented by retrospective
controlled («retrolective») cohort studies using archival
data and guided by a protocol (84–86) and by classical
retrospective controlled cohort studies. If all this does
not work, a look for other sorts of designs is essential
(107). Even prospective one-arm studies can be useful, if
designed and evaluated properly (108,109).
Centers
It is essential to do research in countries or populations
unaware of mistletoe, in general or Iscador in particular
or where mistletoe is not readily available (as in Beograd
or in the USA). The experience from Beograd (Table 1)
shows: randomization is not a real problem; drop-outs
are seldom, since patients are content having a chance to
receive complementary therapy with Iscador; compliance
is high, since patients follow closely the physician’s
instructions.
Outcome
Consider reduction of symptoms, side effects of
conventional therapy (chemotherapy, radiotherapy) and
quality of life in addition to survival and tumor behavior.
26 Controlled studies with mistletoe preparation IscadorPreclinical Studies with Healthy Volunteers
It was pointed out in (110) that there are also few in vivo
controlled studies with healthy volunteers concerning
immunomodulating effects of the mistletoe preparation
Iscador or lectin extracts of mistletoe; however, the
reasons are unknown. The trial in (110) complements the
already existing four trials (111–117). Such research could
be important for design of further clinical trials
investigating the immunological effects of mistletoe
preparations.
Conclusion
Randomized mistletoe research has been notoriously
difficult to perform, especially in German speaking
countries where mistletoe preparations are readily avail-
able outside of clinical trials. Patient and physician
preference in favor of or against complementary therapy
with mistletoe seem to be the most important factors
limiting implementation of such trials with Iscador. This
adds to the overall unwillingness of participation in trials
for patients with serious diseases. Hence a well balanced
mix of designs using different research methods and
different outcomes is suggested, combined with research
in countries, where mistletoe in general or Iscador in
particular are unknown or unavailable.
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